Regencell Bioscience Holdings Limited (RGC) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - Specialty & Generic industria. La empresa tiene su sede en Causeway Bay, Hong Kong. El CEO actual es Yat-Gai Au.
RGC tiene fecha de IPO 2021-07-16, 12 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $14.89B.
Regencell Bioscience Holdings Limited is a Traditional Chinese medicine bioscience company incorporated in 2014 and headquartered in Causeway Bay, Hong Kong. The company specializes in the research, development, and commercialization of TCM-based treatments for neurocognitive disorders and degeneration, with a primary focus on attention deficit hyperactivity disorder and autism spectrum disorder. Through its integrated approach to traditional medicine and modern science, Regencell aims to address significant unmet medical needs in neurological health.
